Sunday 18 October 2026
Export BDTX’s income statement to Excel — free account
Black Diamond Therapeutics, Inc.
BDTX Healthcare Biotechnology
Black Diamond Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $70.0 million. In the quarter to June 2026, EPS grew 10.5% and free cash flow grew 12.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
1.72
0.02
−1.15%
Follow BDTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
6.23 | — | — | — | — | — | — | — | — |
Altman Z-Score |
(0.10) | — | — | — | — | — | — | — | — |
P/S ratio |
0.00 | — | — | — | — | — | — | — | — |
P/FCF ratio |
4.66 | — | — | — | — | — | — | — | — |
Altman Z″-Score (non-manufacturers) |
(0.83) | — | — | — | — | — | — | — | — |
P/Operating CF |
(20.36) | — | — | — | — | — | — | — | — |
P/B ratio |
1.23 | — | — | — | — | — | — | — | — |
Price to Tangible BV |
1.23 | — | — | — | — | — | — | — | — |
EV/Sales |
0.00 | — | — | — | — | — | — | — | — |
EV/EBITDA |
0.74 | — | — | — | — | — | — | — | — |
EV/Operating CF |
0.32 | — | — | — | — | — | — | — | — |
EV/FCF |
0.32 | — | — | — | — | — | — | — | — |
Quick Ratio |
8.18 | 4.79 | 6.69 | 8.05 | 8.87 | 22.16 | 31.80 | 20.06 | 3.53 |
Current Ratio |
8.42 | 4.92 | 6.82 | 8.37 | 9.12 | 22.48 | 32.02 | 20.07 | 3.55 |
Net Debt/EBITDA |
(10.01) | 1.26 | 1.53 | 1.33 | 1.66 | 4.53 | 5.28 | 5.83 | (1.12) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (1.87) |
Asset Turnover |
0.53 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
1.32 | 0.89 | 0.81 | 0.93 | 0.80 | 0.78 | 0.70 | 0.95 | 0.51 |
Capex/Depreciation |
0.08 | 0.27 | 0.14 | (0.36) | (13.22) | (2.73) | (0.45) | (1.73) | 0.00 |
Interest Coverage |
— | — | — | (45.71) | (36.63) | (69,570.00) | — | (2,226.00) | (126.74) |
| 22.88% | (69.67%) | (70.94%) | (58.52%) | (49.87%) | (51.61%) | 112.47% | 80.40% | 41.43% | |
| 16.84% | (49.55%) | (52.37%) | (45.14%) | (43.51%) | (27.57%) | (33.56%) | (34.47%) | (15.38%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
19.11% | (84.98%) | (71.00%) | (79.26%) | (64.38%) | (22.00%) | (23.35%) | (18.14%) | (79.54%) |
Average Days of Receivables |
0.00 | — | — | — | — | — | — | — | — |
Research and Development Expense of Revenue |
47.94% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
23.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
9.47% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
Graham Net Nets |
0.74 | — | — | — | — | — | — | — | — |
Graham Number |
4.16 | — | — | — | — | — | — | — | — |
Earnings Yield |
16.05% | — | — | — | — | — | — | — | — |
Free Cash Flow Yield |
21.45% | — | — | — | — | — | — | — | — |
Revenue per Share |
1.23 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
0.52 | (1.13) | (1.52) | (2.34) | (2.77) | (1.58) | (11.89) | (4.19) | (0.07) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.07) | 0.00 | (0.01) | (0.04) | 0.00 |
Free Cash Flow per Share |
0.52 | (1.13) | (1.52) | (2.35) | (2.84) | (1.59) | (11.90) | (4.22) | (0.07) |
Cash per Share |
2.26 | 1.79 | 2.99 | 3.38 | 5.80 | 9.57 | 74.50 | 25.59 | 0.22 |
Shareholders Equity per Share |
1.97 | 1.51 | 2.66 | 3.18 | 5.41 | 9.35 | (22.72) | (7.70) | (0.19) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.97 | 1.51 | 2.66 | 3.18 | 5.41 | 9.35 | (22.72) | (7.70) | (0.19) |
Free Cash Flow |
29.64 | (62.21) | (66.65) | (85.26) | (102.86) | (52.29) | (24.69) | (8.53) | (2.35) |
Working Capital |
116.71 | 80.60 | 114.39 | 112.45 | 192.06 | 305.34 | 150.85 | 49.11 | 5.68 |
Capital Expenditures |
0.03 | 0.09 | 0.06 | (0.18) | (2.71) | (0.14) | (0.02) | (0.08) | (0.08) |
Net Current Asset Value |
101.64 | 61.82 | 92.20 | 87.15 | 163.92 | 297.64 | (49.74) | (15.68) | (6.78) |
EV/EBIT |
0.76 | — | — | — | — | — | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Price to Operating Income |
11.04 | — | — | — | — | — | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.89 | 0.25 | 0.25 | 0.20 | 0.07 | 0.14 | 0.29 | 0.33 | 0.24 |
Cash ROIC |
12.31% | (34.21%) | (26.86%) | (35.75%) | (25.35%) | (8.40%) | (22.97%) | (23.62%) | (17.21%) |
Accounts Receivable Turnover |
0.00 | — | — | — | — | — | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.08 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2,311.67 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Payables |
2.29 | 3.17 | 2.10 | 2.99 | 3.32 | 2.25 | 1.19 | 0.28 | 0.28 |
Average Assets |
132.83 | 140.60 | 157.41 | 201.97 | 288.68 | 243.98 | 105.06 | 25.91 | 29.92 |
Average Common Equity |
97.75 | 100.01 | 116.22 | 155.80 | 251.83 | 130.30 | (31.35) | (11.11) | (11.11) |
Columns are period end dates